Marksans Pharma Limited (MARKSANS) AI Stock Analysis

• Market Cap: ₹80.19B
• Dividend Yield: 0.45%
• Average Volume (3M): 99.03K
• Price to Earnings (P/E): 22.9
• Beta (1Y): 1.74
• Revenue Growth: 16.94%
• EPS Growth: 4.90%
• Country: IN
• Employees: 1,141
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 1.30
• Shares Outstanding: 453,163,760
• 10 Day Avg. Volume: 119,310
• 30 Day Avg. Volume: 99,030
• PEG Ratio: 1.24
• Price to Book (P/B): 4.08
• Price to Sales (P/S): 3.83
• P/FCF Ratio: 298.02
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹198.00
• Price Target Upside: 11.90% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 70 Neutral
• Price Target: ₹198.00 ▲(11.90% Upside)

Marksans Pharma Limited's overall stock score is driven primarily by its strong financial performance, characterized by robust revenue growth and solid profit margins. However, technical analysis indicates potential bearish trends, and the valuation suggests the stock is fairly valued with a low dividend yield. The absence of earnings call data and notable corporate events means these factors do not influence the score.

Marksans Pharma Limited Business Overview & Revenue Model

Company Description

Marksans Pharma Limited (MARKSANS) is a global pharmaceutical company headquartered in India, engaged in the development, manufacturing, and marketing of generic pharmaceuticals, over-the-counter (OTC) products, and nutraceuticals. The company operates primarily in the pharmaceutical sector and is involved in various therapeutic segments such as pain management, anti-infectives, and cardiovascular medications. Marksans Pharma focuses on delivering high-quality, affordable medicines to meet the healthcare needs of patients worldwide, leveraging its robust R&D capabilities and a diverse product portfolio.

How the Company Makes Money

Marksans Pharma generates revenue through multiple streams, primarily from the sale of generic pharmaceuticals and OTC products. The company's revenue model is based on manufacturing and distributing prescription medications to healthcare providers, hospitals, and pharmacies, both in domestic and international markets. Significant revenue comes from its operations in regulated markets such as the United States, Europe, and Australia, where it offers a range of generic drugs that compete with branded counterparts. Additionally, Marksans engages in contract manufacturing for other pharmaceutical companies, providing a steady income stream. Strategic partnerships with global healthcare providers and distributors further enhance its market reach and sales. The company also invests in R&D to develop new formulations and expand its product lines, which is essential for maintaining competitiveness and driving future revenue growth.

Marksans Pharma Limited Financial Statement Overview

Summary

Marksans Pharma Limited demonstrates robust financial health with strong revenue growth, impressive profit margins, and a solid balance sheet with low leverage. Despite a decrease in cash flow from operations, efficient capital expenditure management has led to increased free cash flow. The company's overall financial position is strong, although monitoring cash flow volatility is advisable.

Income Statement

Marksans Pharma Limited shows a strong revenue growth trajectory with a 20.45% increase from the previous year. The Gross Profit Margin remains solid at 56.38% for the latest period, indicating effective cost management. The Net Profit Margin also improved to 14.51%, reflecting enhanced profitability. Margins such as EBIT at 43.04% and EBITDA at 20.15% showcase operational efficiency. Overall, the income statement indicates a strong financial performance with robust growth and profitability.

Balance Sheet

The balance sheet reflects a healthy financial position with a strong Equity Ratio of 76.14%, suggesting a low reliance on debt for financing. The Debt-to-Equity Ratio remains low at 0.13, indicating minimal financial leverage. Return on Equity (ROE) stands at 15.42%, showing good returns to shareholders. The company's stability is further reinforced by a substantial stockholders' equity base, though the moderate increase in total liabilities warrants attention.

Cash Flow

Cash flow statements reveal a noticeable decrease in Operating Cash Flow by 10.28% compared to the previous year. However, Free Cash Flow saw a significant increase by 56.44%, indicating improved cash management despite lower operating cash flow. The Operating Cash Flow to Net Income Ratio of 0.54 suggests some volatility in cash generation relative to profits. Overall, cash flow performance is solid but highlights areas for potential improvement in cash generation from operations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	26.52B	26.23B	21.77B	18.52B	14.80B	13.68B
Gross Profit	15.08B	14.79B	11.03B	9.31B	7.32B	7.50B
EBITDA	5.43B	5.29B	5.09B	3.99B	3.01B	3.46B
Net Income	3.50B	3.81B	3.14B	2.66B	1.85B	2.39B
Balance Sheet
Total Assets	0.00	32.40B	26.81B	21.90B	16.40B	12.28B
Cash, Cash Equivalents and Short-Term Investments	7.06B	7.05B	7.00B	7.19B	3.47B	2.12B
Total Debt	0.00	3.22B	2.44B	1.23B	1.11B	341.02M
Total Liabilities	-24.89B	7.50B	5.95B	4.25B	4.17B	3.23B
Stockholders Equity	24.89B	24.67B	20.65B	17.45B	12.02B	8.86B
Cash Flow
Free Cash Flow	0.00	337.45M	215.69M	1.84B	529.27M	1.32B
Operating Cash Flow	0.00	2.07B	2.30B	2.37B	992.57M	1.79B
Investing Cash Flow	0.00	-490.09M	-1.41B	-2.59B	-416.86M	-448.96M
Financing Cash Flow	0.00	-651.46M	-687.27M	1.98B	795.11M	-152.86M

Marksans Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 176.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MARKSANS, the sentiment is Neutral. The current price of 176.95 is above the 20-day moving average (MA) of 171.62, below the 50-day MA of 177.16, and below the 200-day MA of 223.59, indicating a neutral trend. The MACD of -0.22 indicates Negative momentum. The RSI at 52.29 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:MARKSANS.

Marksans Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	76 Outperform	₹639.72B	18.86	―	0.36%	7.76%	-2.84%
DRREDDY	74 Outperform	₹1.05T	18.44	―	0.64%	15.86%	2.02%
MARKSANS	70 Neutral	₹80.19B	22.90	―	0.45%	16.94%	4.90%
IPCALAB	60 Neutral	₹326.29B	41.91	―	0.31%	11.49%	35.00%
LAURUSLABS	55 Neutral	₹485.71B	95.39	―	0.13%	17.31%	242.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GLENMARK	48 Neutral	₹525.25B	69.69	―	0.13%	10.99%	―

Marksans Pharma Limited Corporate Events

Marksans Pharma Announces AGM Notice Addendum

Marksans Pharma Limited has announced an addendum to the notice of its 33rd Annual General Meeting, as published in the Business Standard and Lakshadeep newspapers. This announcement is part of the company’s compliance with regulatory requirements, reflecting its commitment to transparency and effective communication with stakeholders.

Marksans Pharma Appoints New Secretarial Auditor for Five-Year Term

Marksans Pharma Limited has announced the appointment of M/s Jinesh Dedhia & Associates as the Secretarial Auditor for a five-year term starting from April 1, 2025, to March 31, 2030. This strategic move is part of the company’s compliance with regulatory requirements and aims to enhance its governance practices, potentially strengthening its market position and stakeholder confidence.